SecBot SecBot

OLMA

Olema Oncology, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001750284 Biotech & Drug Discovery
$7.36 −0.20 (−2.65%)
Nov 16 4:00 PM ET · prev $7.56
Market cap
$658.8M
Small cap
Consensus
Buy
89% Buy or better · 18 analysts
Median target
$35.50
+382% · range $13.00–59.00
1 year
−13.6%
from $8.52 · Nov 17
30 days
+3.5%
from $7.11
52-week range
$6.41–35.83
−79% from high · low Oct 23
Avg volume 20D
1.51M
shares / day
Short interest
17.12M
≈19.6% of shares · +9.2%
Days to cover
11.9
at average volume
Insider net
−$1.2M
0 buyers · 2 sellers · 12 mo
New fund stakes
0
Q3 2026 13F · 0 exits
Filing reports
14
analyzed by SecBot
SecBot read MIXED 7 reports · 90 days
Balance 0 bearish · 0 bullish · 7 neutral oldest → newest, height = score
Avg score ·High conf. 5/7

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBEARISH

    2 insiders sold $1.2M.

  • InstitutionsBULLISH

    Q3 2026: 23 added (0 new), 12 trimmed or exited.

  • AnalystsBULLISH

    16 of 18 rate it Buy or better. Every target is above the price.

  • EstimatesFALLING

    Current-quarter EPS estimate −$0.579 → −$0.634 over 90 days. 1 up, 7 down in 30 days.

  • Short sellersSTEADY

    Short interest +9.2% to 17.12M shares. 11.9 days to cover, ≈19.6% of shares.

  • TrendRANGE

    9% below its 50-day average.

Who's buying

13F· Q3 2026
0
new positions
0
exits
FundMoveSharesValue
MORGAN STANLEYADD2,378,554$20.6M
Candriam S.C.A.ADD1,184,467$10.3M
UBS Group AGADD295,681$2.6M
Squarepoint Ops LLCTRIM198,826$1.7M
ALPS ADVISORS INCADD115,947$1.0M
Connor, Clark & Lunn Investment Management Ltd.ADD106,205$917.6K
Creative PlanningADD96,147$830.7K
Quantinno Capital Management LPADD78,073$674.6K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

18 analysts
Buy 89% rate it Buy or better
Strong Buy6Buy10Hold2Sell0Strong Sell0
12-month targets · 10 analysts

Price is below the lowest target. Median implies +382%.Targets as of Nov 17, 2026.

Recent actions
DateFirmActionRating
Sep 14, 2026Stifel
MAINTAIN
MAINTAINBuy
Aug 13, 2026JP Morgan
MAINTAIN
MAINTAINOverweight
Aug 11, 2026Citigroup
MAINTAIN
MAINTAINBuy
Aug 11, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$1.2M
sold · 2 insiders
DateInsiderTypeValue
Sep 1, 2026
O'Byrne Jason
CHIEF FINANCIAL OFFICER
Sep 1, 2026
AWARD650,000 sh
Jul 24, 2026
Harmon Cyrus
Director
Jul 24, 2026
SELL$146.4K
Jul 23, 2026
Harmon Cyrus
Director
Jul 23, 2026
SELL$144.7K
Jun 18, 2026
Graham G. Walmsley
Director
Jun 18, 2026
AWARD29,500 sh
Jun 18, 2026
RAPPAPORT ANDREW
Director
Jun 18, 2026
AWARD29,500 sh
Jun 18, 2026
Raman Prakash
Director
Jun 18, 2026
AWARD29,500 sh
Jun 18, 2026
Horning Sandra
Director
Jun 18, 2026
AWARD29,500 sh
Jun 18, 2026
Larson Yi
Director
Jun 18, 2026
AWARD29,500 sh

Earnings setup

Estimates
−$0.63
EPS estimate, this quarter
−9%
estimate change, 90 days
1↑ 7↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.63-$0.73–-$0.50+0.0%$0.00
Next Q-$0.70-$0.81–-$0.63-16.0%$0.00
Current FY-$2.56-$3.13–-$2.14-7.6%$0.00
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
17,124,622
shares short
+9.2%
vs prior settlement
11.9
days to cover
≈19.6%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 Other
🔒 Fresh data, subscribers only
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 12, 2026 SEC
Olema Pharmaceuticals, Inc. changed its corporate name to Olema Oncology, Inc. via an Eighth Amended and Restated…
8-K · Impact 2/10
Nov 10, 2026 SEC
Olema Oncology reported Q3 2026 net loss of $73.6M ($0.73 per share) vs. consensus $-0.63, with no revenue. The…
PRESS-RELEASE · Impact 4/10
Oct 2, 2026 Press
Olema Oncology granted inducement stock options for 235,950 shares to six new employees at $8.27/share, vesting over…
Impact 2/10
Sep 30, 2026 Inst.
MORGAN STANLEY · ADD
2,378,554 shares ($20.6M)
Sep 30, 2026 Inst.
Candriam S.C.A. · ADD
1,184,467 shares ($10.3M)
Sep 1, 2026 Insider
O'Byrne Jason was granted 650,000 shares
CHIEF FINANCIAL OFFICER
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
2 drugs tracked · Drug pipeline →
Recent
Nov 16, 2026
Press release
🔒 Fresh data, subscribers only
Nov 12, 2026
Press release
Olema Oncology Announces Corporate Name Change
SAN FRANCISCO, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.) (“Olema” or “Olema Oncology”, Nasdaq…
Nov 10, 2026
Earnings
Olema Oncology Reports Third Quarter 2026 Financial and Operating Results
SAN FRANCISCO, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage…
Nov 10, 2026
Earnings result
OLMA Q3 2026 Earnings: EPS $-0.73 (-14.5% vs est)
Nov 3, 2026
Press release
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage…

SecBot reports

14 filings · 6 press releases · 2 bullish · 1 bearish · 11 neutral
All OLMA filing & press-release reports (20)